Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H36F3N3O2 |
Molecular Weight | 455.5567 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(CC[C@](CN2CCC3=C(C2)C=C(C=N3)C(F)(F)F)(C1)C(C)C)N[C@H]4CCOC[C@H]4OC
InChI
InChIKey=UNVWTBOGMHPKJM-CWKRKGSWSA-N
InChI=1S/C24H36F3N3O2/c1-16(2)23(7-4-19(11-23)29-21-6-9-32-14-22(21)31-3)15-30-8-5-20-17(13-30)10-18(12-28-20)24(25,26)27/h10,12,16,19,21-22,29H,4-9,11,13-15H2,1-3H3/t19-,21+,22-,23-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24984897
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24984897
MK-0812 is a potent and selective CCR2 antagonist, which was developed by Merck. This drug has entered clinical trials for both rheumatoid arthritis and multiple sclerosis. However, the rheumatoid arthritis trial was terminated because of lack of favorable outcomes when MK-0812 failed to show any early clinical improvement. The outcome of the multiple sclerosis trial of MK-0812 also had negative outcomes.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19913021
Curator's Comment: # Merck Research Laboratories
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4015 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20004647 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
yes [IC50 16.933 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00542022
MK0812 once daily for 12 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19906300
MK0812 inhibited the binding of 125I-labeled recombinant human CCL2 to CCR2-containing mouse cell membranes with an IC50 of 19 nM in the presence of 97% mouse plasma. Similarly, MK0812 potently inhibited CCL2-mediated chemotaxis of WEHI-274.1 cells with an IC50 = 5 nM in the presence of 99% mouse plasma. The inhibition of WeHi-274.1 cell chemotaxis was tested with the concentrations of MK0812 (0.3 – 300 nM).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
71587773
Created by
admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
|
PRIMARY | |||
|
DTXSID9047336
Created by
admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
|
PRIMARY | |||
|
624733-88-6
Created by
admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
|
PRIMARY | |||
|
P3LKY4ZL5O
Created by
admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
|
PRIMARY | |||
|
300000041496
Created by
admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
|
PRIMARY | |||
|
DB11990
Created by
admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY